Abstract:While it is now accepted that the gut microbiota contribute to the genotype-environment-lifestyle interactions triggering inflammatory bowel disease (IBD) episodes, efforts to identify the pathogen(s) that cause these diseases have met with limited success. The advent of culture-independent techniques for characterizing the structure and/or function of microbial communities (hereafter referred to as metagenomics) has provided new insights into the events associated with the onset, remission and recurrence of IBD. A large number of observational and/or case-control studies of IBD patients have confirmed substantive changes in gut bacterial profiles (dysbiosis) associated with disease. These types of studies have been augmented by new profiling approaches that support the identification of more ‘colitogenic' bacteria from numerically predominant taxa. Evidence of alterations in lesser abundant taxa such as the methanogenic archaea, to favor types that are more immunogenic, has also been forthcoming. Several recent longitudinal studies of patients with Crohn's disease have produced additional insights, including evidence for the role of ‘anti-inflammatory' microbiota in providing a protective effect and/or promoting remission. In summation, the implications of dysbiosis and restoration of a ‘healthy microbiota' in IBD patients requires definition beyond a taxonomic assessment of the changes in the gut microbiota during disease course. The available evidence does suggest that specific members of the gut microbiota can contribute either pro- or anti-inflammatory effects, and their ecological fitness in the large bowel affects the onset and recurrence of IBD. While metagenomics and related approaches offer the potential to provide novel and important insights into these microbiota and thereby the pathophysiology of IBD, we also need to better understand factors affecting the ecological fitness of these microbes, if new treatment of IBD patients are to be delivered.

The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Interplay of Intestinal Microbiota and Mucosal Immunity in Inflammatory Bowel Disease: a Relationship of Frenemies

The diagnostic and prognostic potential of gut bacteria in inflammatory bowel disease

Gut microbiota and inflammatory bowel disease: The current status and perspectives

The emerging role of the gut microbiota and its application in inflammatory bowel disease

Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease

Noninvasive, microbiome-based diagnosis of inflammatory bowel disease

Recent Progress on the Role of Gut Microbiota in the Pathogenesis of Inflammatory Bowel Disease.

Fecal microbiota and metabolites in the pathogenesis and precision medicine for inflammatory bowel disease

Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives

Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease

The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease

The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy

The Role of the Microbiome in the Etiology of Inflammatory Bowel Diseases

Association between intestinal microbiota and inflammatory bowel disease

The Role of Gut Microbiota Dysbiosis in the Occurrence and Development of Inflammatory Bowel Disease and Its Prevention and Control Strategies

The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

The Gut Microbiota In The Pathogenesis And Therapeutics Of Inflammatory Bowel Disease

The microbiome in inflammatory bowel disease: current status and the future ahead